Tag: biotechnology industry

December 1, 2017

3D Signatures Inc. Announces Upsizing of $1,500,000 Private Placement, the Appointment of a New Director and Reports on AGM Results

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce an upsize of its previously announced...
November 30, 2017

3D Signatures Reports First Quarter Financial Results for Fiscal 2018

3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based...
November 27, 2017

3D Signatures Inc. Announces Non-Brokered Private Placement to Raise $1,500,000 and Updates Previously Announced Brokered Private Placement

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS“) is pleased to announce its intention to raise $1.5 million...
October 25, 2017

3D Signatures Inc. Announces Brokered Private Placement

3D Signatures Inc. (TSXV:DXD)(OTCQB:TDSGF)(FRANKFURT:3D0) (the "Company" or "3DS") is pleased to announce that it has appointed a syndicate of agents...
October 19, 2017

3D Signatures Announces Changes to Its Board of Directors and Audit Committee

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce the addition of Keith Cassidy to...
August 21, 2017

Akari Therapeutics Appoints New CEO

Akari Therapeutics announced the appointment of Dr. David Horn Solomon as CEO starting on August 28.
April 11, 2017

3D Signatures Announces Appointment of Dr. Kevin Little as Chief Scientific Officer

3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF)  (the “Company” or “3DS”), is pleased to announce the appointment of Dr. Kevin Little, subject to...